[Chronic lymphocytic leukemia: when to start a specific treatment?]

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Context:

• Early-intermediate stage chronic lymphocytic leukemia (CLL) management requires clear guidelines.
• Identifying high-risk patients at diagnosis is crucial for timely intervention.
• Distinguishing between low-risk and high-risk CLL impacts treatment decisions.

Purpose:

• To review existing literature and propose evidence-based guidelines for managing early-intermediate stage CLL.
• To define clinical and biological parameters for stratifying CLL patients into high-risk and low-risk groups.
• To establish criteria for initiating treatment versus observation in CLL management.

Summary:

• Clinical and biological parameters can identify high-risk CLL patients prone to disease progression, including anemia, thrombocytopenia, bone marrow infiltration, rapid lymphocyte doubling time, splenomegaly, lymphadenopathy, systemic symptoms, or autoimmune complications.
• Patients lacking these high-risk indicators are classified as low-risk CLL.
• For low-risk CLL, current evidence does not support a survival benefit from treatment; therefore, regular physical examination and complete blood counts are recommended for follow-up.

Impact:

• Provides a framework for clinicians to manage early-intermediate stage CLL effectively.
• Aims to optimize patient care by tailoring treatment strategies based on risk stratification.
• Highlights the importance of monitoring low-risk CLL patients without unnecessary interventions, potentially reducing treatment-related toxicities.